Indietro

Cytek Biosciences Inc

Ticker: CTKB ISIN: US23285D1090
Aggiungi al portafoglio Analisi del portafoglio in 2min
Stock Small-cap High beta
Capitalizzazione
833,41 Mln $
Forward P/E
370,37
Profit margin
-5,05%
Revenue growth QoQ
7,30%
Beta
1,32
4,44 $ -7,69%
Prezzo al 2026-08-24 · NASDAQ

Performance per periodo

Rendimenti cumulativi
1 Month +0,68%
6 Months +1,83%
1 Year +8,03%
5 Years -27,94% p.a.-80,54%
Since inception -24,67% p.a.-76,33%
Rendimenti per anno
YTD -12,08%
2025 -22,19%
2024 -28,84%
2023 -10,68%
2022 -37,44%

Key stats

Market cap
833,41 Mln
Beta
1,32
52-week range
4.66 - 9.87
50-day MA
5,77
200-day MA
6,01
Section 1

Business overview

Company profile data from fundamentals.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Sector Healthcare
Industry Medical Devices
Country United States
Exchange NASDAQ
Section 2

Financial quality

Above-average volatility

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -2,54%
ROA -2,74%
Profit margin -5,05%
Operating margin -8,25%
Revenue/share TTM 1,53
Revenue TTM 201,21 Mln
EBITDA -15,16 Mln
Gross profit TTM 100,97 Mln
Beta 1,32

Valuation

Trailing P/E 0,00
Forward P/E 370,37
P/B 2,16
P/S 4,14
EV/EBITDA -133,96
EV/Revenue 2,83
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 0,10
Quarterly earnings growth 65,80%
Revenue TTM 201,21 Mln
Reported quarters 17
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0,00%
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 12,25 $
Analyst rating 4

Ownership & short interest

Shares outstanding 128,81 Mln
Shares float 110,66 Mln
Institutional ownership 59,02%
Insider ownership 8,85%
Short ratio 5,01
Short % of float 4,11%

Details

Instrument metadata and source update timestamps.

Symbol CTKB
Name Cytek Biosciences Inc
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US23285D1090
Country USA
Code + exchange CTKB.NASDAQ
Fundamentals updated 2024-12-08

Le informazioni fornite su questa piattaforma hanno solo scopo informativo e non devono essere considerate consulenza finanziaria o di investimento. Insightfolio non fornisce consulenza d'investimento, raccomandazioni personalizzate o indicazioni relative all'acquisto, alla detenzione o alla vendita di strumenti finanziari. Gli strumenti e i contenuti sono destinati esclusivamente a finalita educative e non sono adattati alle circostanze individuali, alle esigenze finanziarie o agli obiettivi personali.

Insightfolio non si assume alcuna responsabilita per l'accuratezza, la completezza o l'affidabilita delle informazioni presentate. Gli utenti sono gli unici responsabili della verifica delle informazioni e dell'assunzione di decisioni indipendenti basate sulla propria ricerca e su un'attenta valutazione. L'uso della piattaforma non deve sostituire la consulenza di professionisti finanziari qualificati.

Gli investimenti comportano rischi. Gli utenti devono essere consapevoli che il valore degli investimenti puo variare e che i rendimenti passati non sono indicativi di risultati futuri. Le decisioni di investimento devono basarsi sugli obiettivi finanziari personali, sulla tolleranza al rischio e su una valutazione indipendente delle informazioni rilevanti.

Insightfolio non approva ne garantisce l'idoneita di alcun prodotto finanziario, titolo o strategia specifica. Eventuali proiezioni, previsioni o scenari ipotetici presentati sulla piattaforma hanno solo scopo illustrativo e non costituiscono garanzia di risultati futuri.

Accedendo ai servizi, alle informazioni o ai contenuti offerti da Insightfolio, gli utenti riconoscono e accettano i presenti termini di esclusione di responsabilita. Se non accetti questi termini, ti invitiamo a non utilizzare la piattaforma.

Instrument logos provided by Elbstream.